A Phase 1 interventional study of Metronidazole and Metronidazole in Healthy, sponsored by Teva Pharmaceuticals USA. Completed at 1 site in United States. Open to female participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2010-06-29.
Sponsored by Teva Pharmaceuticals USA (part of Teva Pharmaceutical Industries, Ltd.) · Phase 1 and Interventional
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The primary object of this study was to evaluate the relative bioavailability of the test formulation of metronidazole vaginal gel with the already marketed reference formulation MetroGel-Vaginal Gel® in healthy adult female subjects.
Criteria for Evaluation: FDA Bioequivalence Criteria
Statistical Methods: FDA Bioequivalence Statistical Methods
Teva Pharmaceuticals USA is the lead sponsor of 176 studies on the registry; none are open to participants now.
Of its 5 completed or terminated interventional studies of FDA-regulated products, 4 (80%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metronidazole Vaginal Gel
Drug: Metronidazole
MetroGel-Vaginal®
Drug: Metronidazole
Vaginal Gel, 0.75%
Vaginal Gel, 0.75%
Also known as: MetroGel-Vaginal®
Cmax (Maximum Observed Concentration of Drug Substance in Plasma)
Bioequivalence based on Cmax.
Time frame: Blood samples collected over a 60 hour period.
AUC0-t (Area Under the Concentration-time Curve From Time Zero to Time of Last Measurable Concentration)
Bioequivalence based on AUC0-t.
Time frame: Blood samples collected over a 60 hour period.
AUC0-inf (Area Under the Concentration-time Curve From Time Zero to Infinity)
Bioequivalence based on AUC0-inf.
Time frame: Blood samples collected over a 60 hour period.
| Milestone | Test (Metronidazole) First | Reference (MetroGel-Vaginal®) First |
|---|---|---|
| Started | 19 | 19 |
| Completed | 19 | 19 |
| Not completed | 0 | 0 |
| Milestone | Test (Metronidazole) First | Reference (MetroGel-Vaginal®) First |
|---|---|---|
| Started | 19 | 19 |
| Completed | 19 | 19 |
| Not completed | 0 | 0 |
| Milestone | Test (Metronidazole) First | Reference (MetroGel-Vaginal®) First |
|---|---|---|
| Started | 19 | 19 |
| Completed | 18 | 19 |
| Not completed | 1 | 0 |
| Withdrew: Withdrawal by subject | 1 | 0 |
Bioequivalence based on Cmax.
| ng/mL | Test (Metronidazole) | Reference (MetroGel-Vaginal®) |
|---|---|---|
| Cmax (Maximum Observed Concentration of Drug Substance in Plasma) | 281.111 ± 72.222 | 257.194 ± 71.228 |
Bioequivalence based on AUC0-t.
| ng*h/mL | Test (Metronidazole) | Reference (MetroGel-Vaginal®) |
|---|---|---|
| AUC0-t (Area Under the Concentration-time Curve From Time Zero to Time of Last Measurable Concentration) | 5921.046 ± 1713.316 | 5593.855 ± 1683.155 |
Bioequivalence based on AUC0-inf.
| ng*h/mL | Test (Metronidazole) | Reference (MetroGel-Vaginal®) |
|---|---|---|
| AUC0-inf (Area Under the Concentration-time Curve From Time Zero to Infinity) | 5989.237 ± 1737.791 | 5693.259 ± 1735.116 |
Collected over Adverse event data was collected over the course of the study, which was approximately 2 weeks in duration. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Test (Metronidazole) | — | 0/38 (0%) | 10/38 (26.3%) |
| Reference (MetroGel-Vaginal®) | — | 0/38 (0%) | 16/38 (42.1%) |
| Event | Test (Metronidazole) | Reference (MetroGel-Vaginal®) |
|---|---|---|
| HeadacheGeneral disorders | 6/38 | 8/38 |
| NauseaGeneral disorders | 1/38 | 2/38 |
| Blood in UrineGeneral disorders | 1/38 | 2/38 |
| DiarrheaGeneral disorders | 0/38 | 2/38 |
| Abdominal Pain/CrampsGeneral disorders | 2/38 | 0/38 |
| Protein in UrineGeneral disorders | 0/38 | 2/38 |
| Age, Categorical(Participants) | Test (Metronidazole) First | Reference (MetroGel-Vaginal®) First | Total |
|---|---|---|---|
| <=18 years | 0 | 0 | 0 |
| Between 18 and 65 years | 19 | 19 | 38 |
| >=65 years | 0 | 0 | 0 |
| Sex: Female, Male(Participants) | Test (Metronidazole) First | Reference (MetroGel-Vaginal®) First | Total |
|---|---|---|---|
| Female | 19 | 19 | 38 |
| Male | 0 | 0 | 0 |
| Race/Ethnicity, Customized(participants) | Test (Metronidazole) First | Reference (MetroGel-Vaginal®) First | Total |
|---|---|---|---|
| Black | 4 | 8 | 12 |
| Caucasian | 13 | 11 | 24 |
| More Than One | 2 | 0 | 2 |
| Region of Enrollment(participants) | Test (Metronidazole) First | Reference (MetroGel-Vaginal®) First | Total |
|---|---|---|---|
| United States | 19 | 19 | 38 |
The record gives a start of Nov 2001, a primary completion of Nov 2001 and a completion of Jan 2002. It does not say whether these dates are actual or estimated.
Results were first posted in Mar 2010, 8 years 4 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jun 2010. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Metronidazole